CSL reports $3.7 billion loss, appoints first female CEO
CSL appointed Deborah Waterhouse as its first female CEO after posting a $3.7 billion loss.
CSL, an Australian blood plasma and vaccine giant, swung to a $3.7 billion net loss in 2025/26, largely from writedowns on its kidney treatment and iron deficiency businesses. The shock loss compared to a $4.3 billion profit the previous year.
The company has appointed Deborah Waterhouse as its first female chief executive, replacing the boss let go in 2025. Deborah Waterhouse joins in February from ViiV Healthcare, an HIV specialist she led for a decade.
Waterhouse spent years at UK giant GSK running vaccine and primary care operations. CSL's share price sank about 70 per cent from a July 2024 peak of $310 to about $90 in June, hitting a nine-year low.
The slump prompted a plan to cut about 3000 jobs. Interim chief Gordon Naylor said CSL could deliver savings of about $US400 million ($A570 million) for 2026/27.
Why it mattersCSL is a cornerstone of Australia's biotech sector and a major exporter. The turnaround affects investor confidence, jobs, and the company's ability to fund research.
AustraliaCSL is headquartered in Melbourne and employs thousands in Australia. Its recovery matters for local jobs and Australia's global standing in vaccine and plasma science.
✓ Claims checked against the source and corrected before publish. checked 6 h ago
Open this story in InSnip →
